메뉴 건너뛰기




Volumn 117, Issue 1, 2009, Pages 77-81

Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant

Author keywords

Breast cancer; Endometrium; Fulvestrant; Hormonal therapy; Ultrasonography; Uterus

Indexed keywords

AROMATASE INHIBITOR; FULVESTRANT; TAMOXIFEN;

EID: 69049097170     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0248-2     Document Type: Article
Times cited : (7)

References (31)
  • 1
    • 0024561852 scopus 로고
    • Tamoxifen and the uterus and endometrium
    • 10.1016/S0140-6736(89)91741-8
    • P Neven X De Muylder Y Van Belle et al. 1989 Tamoxifen and the uterus and endometrium Lancet 1 375 10.1016/S0140-6736(89)91741-8
    • (1989) Lancet , vol.1 , pp. 375
    • Neven, P.1    De Muylder, X.2    Van Belle, Y.3
  • 2
    • 0026408075 scopus 로고
    • Effects of tamoxifen on the female genital tract
    • 10.1111/j.1749-6632.1991.tb37890.x
    • T Fornander LE Rutquivist N Wilking 1991 Effects of tamoxifen on the female genital tract Ann N Y Acad Sci 622 469 476 10.1111/j.1749-6632.1991. tb37890.x
    • (1991) Ann N Y Acad Sci , vol.622 , pp. 469-476
    • Fornander, T.1    Rutquivist, L.E.2    Wilking, N.3
  • 3
    • 0028287647 scopus 로고
    • Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
    • 10.1016/S0140-6736(94)92466-X
    • RP Kedar TH Bourne TJ Powles et al. 1994 Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial Lancet 343 1318 1321 10.1016/S0140-6736(94)92466-X
    • (1994) Lancet , vol.343 , pp. 1318-1321
    • Kedar, R.P.1    Bourne, T.H.2    Powles, T.J.3
  • 4
    • 0032537990 scopus 로고    scopus 로고
    • Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study
    • 10.1093/jnci/90.18.1371
    • B Fisher JP Constantino DL Wickerham et al. 1998 Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 90 1371 1388 10.1093/jnci/90.18.1371
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1371-1388
    • Fisher, B.1    Constantino, J.P.2    Wickerham, D.L.3
  • 5
    • 27644458191 scopus 로고    scopus 로고
    • Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting
    • 10.1097/01.cco.0000180434.31991.bf
    • L Morales P Neven R Paridaens 2005 Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting Curr Opin Oncol 17 559 565 10.1097/01.cco.0000180434.31991.bf
    • (2005) Curr Opin Oncol , vol.17 , pp. 559-565
    • Morales, L.1    Neven, P.2    Paridaens, R.3
  • 6
    • 34848866584 scopus 로고    scopus 로고
    • The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: Evidence based review
    • R Poole R Paridaens 2007 The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review Curr Opin Oncol 19 564 572
    • (2007) Curr Opin Oncol , vol.19 , pp. 564-572
    • Poole, R.1    Paridaens, R.2
  • 7
    • 33846179352 scopus 로고    scopus 로고
    • Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations
    • 10.1016/j.ejca.2006.09.003
    • B Thuerlimann D Koeberle HJ Senn 2007 Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations Eur J Cancer 43 46 52 10.1016/j.ejca.2006. 09.003
    • (2007) Eur J Cancer , vol.43 , pp. 46-52
    • Thuerlimann, B.1    Koeberle, D.2    Senn, H.J.3
  • 8
    • 19944429637 scopus 로고    scopus 로고
    • Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
    • 10.1093/annonc/mdi021
    • L Morales D Timmerman P Neven et al. 2005 Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients Ann Oncol 16 70 74 10.1093/annonc/mdi021
    • (2005) Ann Oncol , vol.16 , pp. 70-74
    • Morales, L.1    Timmerman, D.2    Neven, P.3
  • 9
    • 27644547479 scopus 로고    scopus 로고
    • Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: A prospective TVUS study
    • O Garrone S Mezi M Occelli 2003 Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study Ann Oncol 14 s22
    • (2003) Ann Oncol , vol.14 , pp. 22
    • Garrone, O.1    Mezi, S.2    Occelli, M.3
  • 10
    • 31544474866 scopus 로고    scopus 로고
    • The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment
    • 10.1093/humrep/dei322
    • S Duffy TL Jackson M Lansdown et al. 2006 The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment Hum Reprod 21 545 553 10.1093/humrep/dei322
    • (2006) Hum Reprod , vol.21 , pp. 545-553
    • Duffy, S.1    Jackson, T.L.2    Lansdown, M.3
  • 11
    • 33644775724 scopus 로고    scopus 로고
    • Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology
    • 10.1158/1078-0432.CCR-05-0225
    • B Gerber A Krause T Reimer et al. 2006 Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology Clin Cancer Res 12 1245 1250 10.1158/1078-0432.CCR-05-0225
    • (2006) Clin Cancer Res , vol.12 , pp. 1245-1250
    • Gerber, B.1    Krause, A.2    Reimer, T.3
  • 12
    • 33750192472 scopus 로고    scopus 로고
    • Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors
    • 10.1016/j.ygyno.2006.04.004
    • G Garuti F Cellani G Centinaio et al. 2006 Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors Gynecol Oncol 103 599 603 10.1016/j.ygyno.2006.04.004
    • (2006) Gynecol Oncol , vol.103 , pp. 599-603
    • Garuti, G.1    Cellani, F.2    Centinaio, G.3
  • 13
    • 33846294351 scopus 로고    scopus 로고
    • Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients
    • 10.1007/s10549-006-9285-x
    • O Markovitch R Tepper A Fishman et al. 2007 Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients Breast Cancer Res Treat 101 185 190 10.1007/s10549-006-9285-x
    • (2007) Breast Cancer Res Treat , vol.101 , pp. 185-190
    • Markovitch, O.1    Tepper, R.2    Fishman, A.3
  • 14
    • 69049095818 scopus 로고    scopus 로고
    • Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment
    • G Bertelli E Hall E Ireland et al. 2007 Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment Breast Cancer Res Treat 106 s111
    • (2007) Breast Cancer Res Treat , vol.106 , pp. 111
    • Bertelli, G.1    Hall, E.2    Ireland, E.3
  • 15
    • 69049091679 scopus 로고    scopus 로고
    • Endometrial safety of cross-over treatment with tamoxifen followed by exemestane
    • DG Kieback N Harbeck W Bauer et al. 2008 Endometrial safety of cross-over treatment with tamoxifen followed by exemestane Eur J Cancer 6 s198
    • (2008) Eur J Cancer , vol.6 , pp. 198
    • Kieback, D.G.1    Harbeck, N.2    Bauer, W.3
  • 16
    • 39749201478 scopus 로고    scopus 로고
    • From endometrial hyperplasia to endometrial cancer: Insight into the biology and possible medical preventive measures
    • MC Boruban K Altundag GS Kilic J Blankstein 2008 From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures Eur J Cancer Prev 17 133 138
    • (2008) Eur J Cancer Prev , vol.17 , pp. 133-138
    • Boruban, M.C.1    Altundag, K.2    Kilic, G.S.3    Blankstein, J.4
  • 17
    • 0035718191 scopus 로고    scopus 로고
    • Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer
    • 10.1016/S0960-0760(01)00138-8
    • JFR Robertson 2001 Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer J Steroid Biochem Mol Biol 79 209 212 10.1016/S0960-0760(01)00138-8
    • (2001) J Steroid Biochem Mol Biol , vol.79 , pp. 209-212
    • Robertson, J.F.R.1
  • 18
    • 22244449598 scopus 로고    scopus 로고
    • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma
    • 10.1002/cncr.21163
    • A Howell J Pippen RM Elledge et al. 2005 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma Cancer 104 236 239 10.1002/cncr.21163
    • (2005) Cancer , vol.104 , pp. 236-239
    • Howell, A.1    Pippen, J.2    Elledge, R.M.3
  • 19
    • 33846543806 scopus 로고    scopus 로고
    • Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
    • 10.1093/annonc/mdl341
    • L Perey R Paridaens H Hawle et al. 2007 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) Ann Oncol 18 64 69 10.1093/annonc/mdl341
    • (2007) Ann Oncol , vol.18 , pp. 64-69
    • Perey, L.1    Paridaens, R.2    Hawle, H.3
  • 20
    • 42149089313 scopus 로고    scopus 로고
    • Fulvestrant (Faslodex) in advanced breast cancer: Clinical experience from a Belgian cooperative study
    • 10.1007/s10549-007-9628-2
    • P Neven R Paridaens G Pelgrims et al. 2008 Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study Breast Cancer Res Treat 109 59 65 10.1007/s10549-007-9628-2
    • (2008) Breast Cancer Res Treat , vol.109 , pp. 59-65
    • Neven, P.1    Paridaens, R.2    Pelgrims, G.3
  • 21
    • 13244290109 scopus 로고    scopus 로고
    • Endocrine treatment options for advanced breast cancer-the role of fulvestrant
    • 10.1016/j.ejca.2004.07.035
    • JF Robertson SE Come SE Jones et al. 2005 Endocrine treatment options for advanced breast cancer-the role of fulvestrant Eur J Cancer 41 346 356 10.1016/j.ejca.2004.07.035
    • (2005) Eur J Cancer , vol.41 , pp. 346-356
    • Robertson, J.F.1    Come, S.E.2    Jones, S.E.3
  • 22
    • 43249130208 scopus 로고    scopus 로고
    • Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
    • 10.1200/JCO.2007.13.5822
    • S Chia W Gradishar L Mauriac et al. 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 10.1200/JCO.2007.13.5822
    • (2008) J Clin Oncol , vol.26 , pp. 1664-1670
    • Chia, S.1    Gradishar, W.2    Mauriac, L.3
  • 23
    • 16644374043 scopus 로고    scopus 로고
    • Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body
    • A Gaducci S Cosio AR Genazzani 2004 Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body Curr Opin Investig Drugs 5 1031 1044
    • (2004) Curr Opin Investig Drugs , vol.5 , pp. 1031-1044
    • Gaducci, A.1    Cosio, S.2    Genazzani, A.R.3
  • 24
    • 0037011660 scopus 로고    scopus 로고
    • A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
    • 10.1038/sj.bjc.6600644
    • S Addo RA Yates A Laight 2002 A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Br J Cancer 87 1354 1359 10.1038/sj.bjc. 6600644
    • (2002) Br J Cancer , vol.87 , pp. 1354-1359
    • Addo, S.1    Yates, R.A.2    Laight, A.3
  • 25
    • 0037835462 scopus 로고    scopus 로고
    • A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy
    • 10.1016/S0015-0282(03)00261-9
    • J Donnez BH Vivancos M Kudela et al. 2003 A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy Fertil Steril 79 1380 1389 10.1016/S0015-0282(03)00261-9
    • (2003) Fertil Steril , vol.79 , pp. 1380-1389
    • Donnez, J.1    Vivancos, B.H.2    Kudela, M.3
  • 26
    • 33845799161 scopus 로고    scopus 로고
    • Fulvestrant: A further treatment option for patients with metastatic uterine cancer?
    • 10.1159/000096541
    • M Lux E Wenkel K Beckmann et al. 2006 Fulvestrant: a further treatment option for patients with metastatic uterine cancer? Onkologie 29 577 580 10.1159/000096541
    • (2006) Onkologie , vol.29 , pp. 577-580
    • Lux, M.1    Wenkel, E.2    Beckmann, K.3
  • 27
    • 30444432701 scopus 로고    scopus 로고
    • Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy
    • 10.1016/j.ygyno.2005.09.011
    • MA Hoffman A Khan 2006 Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy Gynecol Oncol 100 439 441 10.1016/j.ygyno.2005.09.011
    • (2006) Gynecol Oncol , vol.100 , pp. 439-441
    • Hoffman, M.A.1    Khan, A.2
  • 29
    • 0032539466 scopus 로고    scopus 로고
    • Should tamoxifen users be screened for endometrial lesions?
    • 10.1016/S0140-6736(05)78216-7
    • P Neven I Vergote 1998 Should tamoxifen users be screened for endometrial lesions? Lancet 351 155 157 10.1016/S0140-6736(05)78216-7
    • (1998) Lancet , vol.351 , pp. 155-157
    • Neven, P.1    Vergote, I.2
  • 30
    • 0036754549 scopus 로고    scopus 로고
    • Endometrial evaluation is a very important tool in the management of breast cancer patients
    • 10.1016/S0959-8049(02)00292-7
    • M Berlière C Galant A Charles et al. 2002 Endometrial evaluation is a very important tool in the management of breast cancer patients Eur J Cancer 38 suppl. 6 67 68 10.1016/S0959-8049(02)00292-7
    • (2002) Eur J Cancer , vol.38 , Issue.SUPPL. 6 , pp. 67-68
    • Berlière, M.1    Galant, C.2    Charles, A.3
  • 31
    • 33749331845 scopus 로고    scopus 로고
    • Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology
    • 10.1158/1078-0432.CCR-06-0897
    • L Morales R Paridaens D Timmerman P Neven 2006 Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology Clin Cancer Res 12 5603 10.1158/1078-0432.CCR-06-0897
    • (2006) Clin Cancer Res , vol.12 , pp. 5603
    • Morales, L.1    Paridaens, R.2    Timmerman, D.3    Neven, P.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.